Updating results

525 results

Sort: Relevance | Date

Point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast

In development [GID-DG10024] Expected publication date: 13 November 2019

Diagnostics guidance In development

Rapid tests for Group A Streptococcal infections in people with a sore throat

In development [GID-DG10025] Expected publication date: 13 November 2019

Diagnostics guidance In development

Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke

In development [GID-DG10023] Expected publication date: TBC

Diagnostics guidance In development

PredictSURE-IBD and IBDX to guide personalised treatment of Crohn's disease

In development [GID-DG10029] Expected publication date: 08 July 2020

Diagnostics guidance In development

QAngio XA 3D/ QFR and CAAS vFFR imaging software for assessing the functional significance of coronary obstructions during invasive coronary angiography

In development [GID-DG10034] Expected publication date: 30 September 2020

Diagnostics guidance In development

Testing strategies for Lynch syndrome in people with endometrial cancer

In development [GID-DG10033] Expected publication date: 29 July 2020

Diagnostics guidance In development

High-sensitivity troponin for the early rule out of acute myocardial infarction

In development [GID-DG10035] Expected publication date: 26 August 2020

Diagnostics guidance In development

Diabetic foot infection: antimicrobial prescribing

In development [GID-NG10132] Expected publication date: 11 October 2019

Antimicrobial prescribing guideline In development

Cannabis-based medicinal products

In development [GID-NG10124] Expected publication date: 11 November 2019

NICE guideline In development

Indoor air quality at home

In development [GID-NG10022] Expected publication date: 11 December 2019

NICE guideline In development

Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source (ID1417)

Proposed [GID-TA10426] Expected publication date: TBC

Technology appraisal guidance Proposed

Galcanezumab for preventing cluster headache [ID1212]

Proposed [GID-TA10425] Expected publication date: TBC

Technology appraisal guidance Proposed

Pitolisant hydrochloride for treating obstructive sleep apnoea ID1065

Proposed [GID-TA10385] Expected publication date: TBC

Technology appraisal guidance Proposed

Rivaroxaban for treating chronic heart failure [ID1462]

Proposed [GID-TA10393] Expected publication date: TBC

Technology appraisal guidance Proposed

Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy [ID1410]

Proposed [GID-TA10391] Expected publication date: TBC

Technology appraisal guidance Proposed

Upadacitinib for treating moderate to severe rheumatoid arthritis [ID1400]

Proposed [GID-TA10389] Expected publication date: 18 March 2020

Technology appraisal guidance Proposed

Fostamatinib for treating persistent or chronic immune thrombocytopenia [ID1087]

Proposed [GID-TA10387] Expected publication date: TBC

Technology appraisal guidance Proposed

Esketamine for treatment-resistant depression (ID1414)

Proposed [GID-TA10371] Expected publication date: 18 March 2020

Technology appraisal guidance Proposed

Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]

Proposed [GID-TA10332] Expected publication date: TBC

Technology appraisal guidance Proposed

Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]

Proposed [GID-TA10336] Expected publication date: TBC

Technology appraisal guidance Proposed

Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)

Proposed [GID-TA10306] Expected publication date: TBC

Technology appraisal guidance Proposed

Tocilizumab for treating systemic sclerosis (ID1396)

Proposed [GID-TA10346] Expected publication date: TBC

Technology appraisal guidance Proposed

Pegvaliase for treating phenylketonuria [ID1110]

Proposed [GID-TA10345] Expected publication date: TBC

Technology appraisal guidance Proposed

Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery (ID1105)

Proposed [GID-TA10348] Expected publication date: TBC

Technology appraisal guidance Proposed

Intravenous zanamivir for treating influenza in hospital [ID1196]

Proposed [GID-TA10298] Expected publication date: TBC

Technology appraisal guidance Proposed

Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery [ID1149]

Proposed [GID-TA10297] Expected publication date: TBC

Technology appraisal guidance Proposed

STG320 for treating persistent allergic rhinitis caused by house dust mites (ID1278)

Proposed [GID-TA10279] Expected publication date: TBC

Technology appraisal guidance Proposed

Mepolizumab for treating chronic obstructive pulmonary disease (ID1237)

Proposed [GID-TA10239] Expected publication date: TBC

Technology appraisal guidance Proposed

Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis ID1178

Proposed [GID-TA10199] Expected publication date: TBC

Technology appraisal guidance Proposed

Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154

Proposed [GID-TA10198] Expected publication date: TBC

Technology appraisal guidance Proposed

Avelumab for treating metastatic Merkel cell carcinoma (CDF Review of TA517) ID1617

Proposed [GID-TA10545] Expected publication date: 19 September 2020

Technology appraisal guidance Proposed

Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders [ID1319]

Proposed [GID-TA10544] Expected publication date: TBC

Technology appraisal guidance Proposed

Filgotinib for treating moderate to severe rheumatoid arthritis ID1632

Proposed [GID-TA10541] Expected publication date: TBC

Technology appraisal guidance Proposed

Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]

Proposed [GID-TA10542] Expected publication date: TBC

Technology appraisal guidance Proposed

Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]

Proposed [GID-TA10522] Expected publication date: TBC

Technology appraisal guidance Proposed

Olaparib with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer [ID1652]

Proposed [GID-TA10526] Expected publication date: TBC

Technology appraisal guidance Proposed

Ranibizumab for treating diabetic retinopathy [ID1592]

Proposed [GID-TA10521] Expected publication date: TBC

Technology appraisal guidance Proposed

Esketamine for treating major depressive disorder in adults at imminent risk for suicide ID1604

Proposed [GID-TA10518] Expected publication date: TBC

Technology appraisal guidance Proposed

Eculizumab for treating relapsing neuromyelitis optica [ID1271]

Proposed [GID-TA10469] Expected publication date: TBC

Technology appraisal guidance Proposed

Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (CDF Review TA600) ID1683

Proposed [GID-TA10537] Expected publication date: 12 August 2020

Technology appraisal guidance Proposed

Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF Review TA490) ID1585

Proposed [GID-TA10538] Expected publication date: 12 August 2020

Technology appraisal guidance Proposed

Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)

Proposed [GID-TA10527] Expected publication date: TBC

Technology appraisal guidance Proposed

Abicipar pegol for treating wet age-related macular degeneration ID1533

Proposed [GID-TA10511] Expected publication date: TBC

Technology appraisal guidance Proposed

Brentuximab vedotin for untreated CD30-positive peripheral T-cell lymphoma ID1586

Proposed [GID-TA10514] Expected publication date: 12 August 2020

Technology appraisal guidance Proposed

Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer ID1429

Proposed [GID-TA10512] Expected publication date: TBC

Technology appraisal guidance Proposed

Midostaurin for treating advanced systemic mastocytosis ID1573

Proposed [GID-TA10503] Expected publication date: TBC

Technology appraisal guidance Proposed

Luspatercept for treating anaemia caused by myelodysplastic syndromes [ID1550]

Proposed [GID-TA10508] Expected publication date: TBC

Technology appraisal guidance Proposed